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Summary Seven consecutive patients with intra-abdominal desmoplastic small round-cell tumours were screened at presentation for
carcinoembryonic antigen (CEA), Ca19-9, Cal5-3, Ca125, alpha-fetoprotein (AFP), human chorionic gonadotrophin (hCG) and neuron-
specific enolase (NSE). Initially elevated tumour markers were used to monitor therapy and follow-up. Tumour marker assays were all in the
normal range, with the exception of Cal25 and NSE. The Cal25 level was initially high in six of the seven patients (86%) with a median value
of 200 U ml-' and a range of 22-735 U ml-'. The NSE value was elevated before therapy in three of the five patients (60%) for whom assay
results were available, with a median of 19 ng ml-' and a range of 6.8-37.5 ng ml'. Cal25 normalized in five out of six cases and NSE always
normalized during chemotherapy, but neither of these two tumour markers correlated specifically with response, as only one patient
experienced a partial response, five tumour stabilization and the remaining patient tumour progression. At progression, Cal25 was again
elevated in two out of four cases several weeks before clinical relapse and NSE in only one out of three cases. Cal 25 and NSE are frequently
raised in the serum of patients with intra-abdominal desmoplastic small round-cell tumours before therapy, but are not reliable monitors of the
course of the disease. However, normalization is frequently associated with an improvement of symptoms or a moderate clinical response.
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Intra-abdominal small round-cell tumour is a recently recognized
clinicopathological entity (Gerald et al, 1989; Ord6nez et al, 1989).
This rare neoplasm occurs predominantly in children and young
adults and is histologically distinct from other small round-cell
tumours because of its immunohistochemical pattern and the pres-
ence of an abundant desmoplastic stroma (Gerald et al, 1993).
Divergent differentiation is commonly assessed by immunohisto-
chemical staining for epithelial (keratin, epithelial membrane
antigen), neural (neuron-specific enolase) and muscular (desmin)
markers (Gerald et al, 1991; Ord6fiez et al, 1993). A reciprocal
translocation t (11; 22) (pl3; q12) is specific to this entity and is
responsible for fusion-of the EWS and WT1 genes (Ladanyi et al,
1991). This malignancy is hardly chemosensitive and the prognosis
is usually unfavourable, although several cases of partial or
complete response to therapy with long-term survival have been
reported (Gerald et al, 1991; Farhat et al, 1995). Despite the well-
recognized histologically divergent differentiation of this tumour,
no data exist in the literature concerning serum tumour markers in
these patients. In this study, we investigated multiple tumour marker
assays before treatment to determine the relevance of initially
elevated tumour markers for monitoring the course ofthe disease.
PATIENTS AND METHODS
Between November 1991 and November 1994, seven patients
were diagnosed as having intra-abdominal small round-cell
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tumours at the InstitutGustave-Roussy. There were four males and
three females. The mean age atdiagnosis was 22 years, andranged
from 15 to 30 years. All slides were reviewed. Immunostaining for
neuron-specific enolase (NSE) was positive in all cases. Immuno-
staining for Cal25 was not performed. Patients always presented
with a pelvic or abdominal primary involving the peritoneum.
Distant metastases were present in five cases, the liver being the
affected site in three and retroperitoneal lymph nodes in two.
Tumour burden was high in all cases. Surgical debulking was
performed initially in three patients, but measurable residual
tumour persisted in all cases. Chemotherapy was initiated in these
three patients and the four others and consisted of a combination
of doxorubicin, cisplatin, etoposide and cyclophosphamide
(PAVEP regimen) (Arriagada et al, 1993). Tumour response was
assessed every two cycles by pelvic and abdominal computerized
tomography (CT) scan.
Serum carcinoembryonic antigen (CEA), Cal9-9, Cal5-3,
Cal25, human chorionic gonadotrophin (hCG), alpha-fetoprotein
(AFP) and NSE were measured at presentation in our institution
(following debulking in three patients). Tumour markers were not
measured in ascitic fluid.
CEA, Cal9-9, Cal25 and AFP were measured using the
enzyme-linked immunosorbent assay (ELISA)/one-step sandwich
assay. Ca15-3 was measured using the ELISA/two-step sandwich
assay. A radioimmunoassay was used to measure hCG and NSE.
The upper thresholds considered normal for markers were 7 ng
ml-' for CEA, 35 U ml-' for Cal9-9, 30 Ul 1-' for Cal5-3, 35 Ut 1-'
forCal25, 10 MUI 1-' for hCG, 10 ng ml-' forAFP and 12.5 ng ml-'
for NSE. Changes in initially elevated serum tumour markers were
examined during the clinical course of the disease. Determinations
were obtained monthly during chemotherapy and follow-up.
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Table 1 Serum Cal25 and NSE levels at presentation in seven patients with
intra-abdominal desmoplastic small round-cell tumours
No. Age/sex Cal25 NSE Survival
(U ml-') (ng ml-1) (months)
1 23/M 160 21.3 23
2 15/F 255 - 17
3 25/F 200 6.8 22
4 19/F 22 10 23
5 19/M 318 19.5 14+
6 30/M 735 37.5 13+
7 22/M 200 - 21+
RESULTS (Table 1)
CEA, Cal9-9, Cal5-3, AFP and HCG values measured at presen-
tation were always normal. Serum Ca125 was elevated in six
out of seven cases (86%) with a mean of270 U ml-' and a median
of200 U ml-' (range 22-735 U ml-'). Serum NSE was obtained in
five cases before therapy and was elevated in three (60%). The
mean value was 19 ng ml-' and median was 19.5 ng ml-' (range
6.8-37.5 ng ml-').
During chemotherapy, disease assessment showed one partial
response (PR), five cases of stable disease (SD) including two
minor responses, defined as a volume reduction of < 50% (MR),
and one case ofprogressive disease (PD). The clinical outcome of
fourofthese seven patients has been reportedpreviously (Farhat et
al, 1995). Despite this apparent poor response rate, chemotherapy
frequently obtained a significant although non-measurable reduc-
tion of ascitic effusions. Initially elevated Cal25 normalized in
five out ofsix cases, but did not correlate specifically with clinical
response: one PR and four SD including two MR. However, all
these five patients experienced a parallel decrease in their ascitic
effusions. The sole case with a persistently elevated Cal25 level
was a patient with stable disease. The patient with an initially
normal Cal25 level experienced progressive disease, with tumour
markers (Cal25 and NSE) always in the normal range during
follow-up.
The NSE value normalized during therapy in all three cases in
whom it was raised initially. These patients achieved an MR in one
case and SD was noted in two cases.
At progression, the Cal25 assay was performed in four cases,
and the value had increased in two (50%), several weeks before
clinical relapse. Ca125 never normalized in one of these two
patients. NSE was measured concomitantly in three cases and
became elevated at progression in one (33%).
DISCUSSION
Intra-abdominal small round-cell tumours are very rare malignan-
cies and only a few authors have reported series of more than five
patients (Gerald et al, 1991; Varma et al, 1992; Ordofiez et al,
1993; Frappaz et al, 1994; Farhat et al, 1995). Here, we report our
experience ofmultiple tumour marker screening in seven patients.
To our knowledge, such a study has not been reported previously
in the literature.
Our study shows that only two tumour markers are elevated
before therapy in the serum ofpatients with intra-abdominal small
round-cell tumours, Cal25 and NSE. Cal25 is an antigen determi-
nant recognized by the monoclonal antibody, 0C125, that has
been shown to provide useful information during the follow-up
of ovarian carcinomas (Bast et al, 1983; Fisken et al, 1993).
However, this tumour marker is not specific for ovarian carci-
nomas and has been shown frequently to be raised in cases of
ascitic and pleural effusions, benign tumours or other malignan-
cies, particularly advanced non-small-cell lung cancer (Bergman
et al, 1987; Diez et al, 1991). The fact that ascites are frequently
found in patients with intra-abdominal small round-cell tumours
could explain why a high proportion of these patients have an
elevated serum CaI25. Moreover, the frequent regression of
ascites in our patients who received chemotherapy, and who were
practically all affected by this disorder, probably accounts for the
high incidence of Ca125 normalization, unless they were non-
responders. Immunostaining for Ca125 was not performed in our
study. Investigators from the MD Anderson Cancer Centerfound a
positive staining in only one of the five cases tested for Cal25
(Ordoniez et al, 1993).
NSE was elevated in three out offive cases before therapy. NSE
is a glycolytic enzyme that has been shown to be a sensitive
tumour marker in a number of malignancies and especially in
small-cell lung cancer, neuroblastoma and neuroendocrine
tumours (Carney et al, 1982; Pring et al, 1982; Zeltzer et al, 1983).
Strong cellular staining for NSE has already been reported in
neoplastic tissue samples by patients with intra-abdominal small
round-cell tumours using immunohistochemical techniques
(Gonzalez-Crussi et al, 1990; Gerald et al, 1991; Variend et al,
1991; Ord6oez et al, 1993; Frappaz et al, 1994; Farhat et al, 1995).
In the largest study by Ordoniez et al (1993) six of 12 tumour
samples reacted for NSE. In the study by Gerald et al (1991), in
which an immunohistochemical analysis ofNSE was available for
eightpatients, halfofthe cases hadpositive staining. This seems to
be consistent with the three out offive patients with raised serum
NSE levels in our study.
During therapy, serum NSE levels did not seem to correlate
specifically with clinical response. However, if we assume that
the neuroendocrine component of intra-abdominal desmoplastic
small round-cell tumours is likely to be sensitive to chemotherapy,
then this would account for the normalization of serum NSE.
Thus, the lack of clinical response observed here is probably
caused by other drug-resistant tumour components or to the abun-
dant desmoplastic stroma.
At progression, serum Ca125 was raised again in half the
patients and NSE in one ofthree cases. The limited value ofserial
NSE measurements in predicting relapse has been underscored
recently in patients with small-cell lung cancer (Nou et al, 1990;
Johnson et al, 1993; Van Zandwijk et al, 1990). Our experience
of serum NSE in monitoring progression confirms these data
in intra-abdominal small round-cell tumours. However, further
investigation with a larger series is needed to validate these data
definitively.
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